| Literature DB >> 23956766 |
Meng Wu1, Jingqing Hu, Biaoyan Liu.
Abstract
Objective. To realize the current situation and problems of complex interventions' clinical trials. Methods. Searching at Chinese Journal Integrated Traditional and Western Medicine and Journal of Traditional Chinese Medicine from 2007 to 2012 by hand, we identified complex interventions' articles, and then we used the proposed criteria of complex interventions and CONSORT FOR TCM to evaluate. Results. All data is presented as counts with percentages and details in tables. Conclusion. Our evaluation presented that complex interventions have many defects: the selection of the intervention's components lacks rationale, complex interventions were short of fundamental researches, components' interactions were ambiguous, and the advantages of complex interventions were not mentioned. Furthermore, explanation of sample size, blind, quality control, ethical approval, and inform consent were neglected in different degrees.Entities:
Year: 2013 PMID: 23956766 PMCID: PMC3730186 DOI: 10.1155/2013/250690
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Data sources.
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | |
|---|---|---|---|---|---|---|
| Chinese Journal Integrated Traditional and Western Medicine | ||||||
| Clinical trials' article | 181 | 146 | 131 | 99 | 101 | 143 |
| The complex interventions' articles belong to clinical trials | 78 (43.1%) | 44 (30.1%) | 39 (29.8%) | 24 (24.2%) | 31 (30.7%) | 28 (19.6%) |
|
| ||||||
| Journal of Traditional Chinese Medicine | ||||||
| Clinical trials' article | 63 | 68 | 58 | 60 | 155 | 136 |
| The complex interventions' articles belong to clinical trials | 19 (30.2%) | 15 (22.1%) | 14 (24.1%) | 19 (31.7%) | 28 (18.1%) | 48 (35.3%) |
The data of included articles in general.
| Item | Sub-item | Number of reported (%) |
|---|---|---|
| The top five types of diseases that articles involve are | Gynecology and reproductive system diseases | 46 (13.0%) |
| Bone and joint or motion sickness | 41 (11.6%) | |
| Tumor | 39 (11.0%) | |
| Digestive diseases | 37 (10.4%) | |
| Endocrine diseases | 32 (9.0%) | |
|
| ||
| Funding | National | 41 (11.6%) |
| Provincial, ministry, or municipal | 77 (21.8%) | |
| Others | 10 (2.8%) | |
| No explanations | 226 (63.8%) | |
|
| ||
| The department of first author | Colleges, universities, and affiliated hospital | 188 (53.1%) |
| Other hospitals at all levels | 139 (39.3%) | |
| Research institutions | 27 (7.6%) | |
|
| ||
| The number of participating centers | 1 | 316 (89.3%) |
| 2–5 | 32 (9.0%) | |
| 6+ | 6 (1.7%) | |
|
| ||
| Other information | Informed Consent | 137 (38.7%) |
| Ethical approval | 9 (2.5%) | |
| Acknowledgments | 3 (0.8%) | |
The results of using the proposed criteria for evaluation.
| Item | No. | Subitem | Number (%) |
|---|---|---|---|
| The introduction of background which lead to the complex interventions | 1 | Introduction of target disease | 214 (60.5%) |
| Limitations of using single interventions | 145 (41.0%) | ||
| Not mentioned | 93 (26.3%) | ||
|
| |||
| The type of objectives | 2 | Main purpose of observing clinical efficacy | 324 (91.5%) |
| Demonstrate results of former research(es) | 30 (8.5%) | ||
|
| |||
| Rationale for the selection of the intervention's components | 3 | Depend on systematic review results of clinical trials | 1 (0.3%) |
| Based on former clinical trials | 99 (28.0%) | ||
| The results of animal studies | 112 (31.6%) | ||
| Experts consensus | 5 (1.4%) | ||
| Personal clinical experiences | 29 (8.2%) | ||
| Not mentioned | 108 (30.5%) | ||
|
| |||
| Description the theoretical basis of complex interventions' program | 4 | Depend on systematic review results of clinical trials | 0 (0.0%) |
| Based on former clinical trials | 25 (7.1%) | ||
| The results of animal studies | 0 (0.0%) | ||
| Experts consensus | 1 (0.3%) | ||
| Personal clinical experiences | 11 (3.1%) | ||
| Not mentioned | 317 (89.5%) | ||
|
| |||
| Pilot study | 5 | Is there pilot study or not? | 0 (0.0%) |
|
| |||
| Sample size | 6 | <50 | 32 (9.0%) |
| 50–99 | 193 (54.5%) | ||
| 100–299 | 118 (33.3%) | ||
| ≥300 | 11 (3.1%) | ||
|
| |||
| The type of design | 7 | Randomized controlled trials | 312 (88.1%) |
| (i) Randomization | 225 (63.6%) | ||
| (ii) Quasi-randomization | 49 (13.8%) | ||
| (iii) Randomized, no method stated | 38 (10.7%) | ||
| Cohort study | 8 (2.3%) | ||
| Crossover design | 1 (0.3%) | ||
| Case-control study | 1 (0.3%) | ||
| Non-randomized concurrent controlled trials | 32 (9.0%) | ||
|
| |||
| The categories of combinations between intervention's components | 8 | Chinese medicine alone | 113 (31.9%) |
| (i) Chinese medicines with different formulations | 22 (6.2%) | ||
| (ii) Chinese medicines + non-drug | 67 (18.9%) | ||
| (iii) Difference kinds of non-drug TCM | 24 (6.8%) | ||
| Western medicine alone | 0 (0.0%) | ||
| Chinese plus western medicine | 241 (68.1%) | ||
| (i) Chinese medicines + western medicines/basic treatments | 207 (58.5%) | ||
| (ii) Western medicines + non-drug | 20 (5.6%) | ||
| (iii) Chinese medicines + western medicines + non-drug | 14 (4.0%) | ||
|
| |||
| Control interventions | 9 | A single component as effective control | 156 (44.1%) |
| Several components combined as a effective control | 185 (52.3%) | ||
| Placebo control | 12 (3.4%) | ||
| Blank control | 1 (0.3%) | ||
|
| |||
| Indicators for evaluating the outcomes | 10 | One indicator | 116 (32.8%) |
| Multiple indicators for comprehensive evaluation | 238 (67.2%) | ||
|
| |||
| Elaborating interactions between different components | 11 | Interactions lead to better efficacy | 118 (33.3%) |
| (i) Some similar components combined for enhancing the overall efficacy | 60 (16.9%) | ||
| (ii) Components complemented each other to enhance the efficacy | 27 (7.6%) | ||
| (iii) Improved by reducing side effects | 31 (8.8%) | ||
| Interactions lead to worse efficacy | 0 (0.0%) | ||
| (i) Efficacy reduced without side effect | 0 (0.0%) | ||
| (ii) Some side effects generated | 0 (0.0%) | ||
| Not mentioned | 236 (66.7%) | ||
|
| |||
| The advantages of using complex interventions' program | 12 | More effective | 297 (83.9%) |
| Shorten the treatment time | 24 (7.6%) | ||
| Fewer side effects (security) | 96 (27.1%) | ||
| Easier to implement | 19 (5.4%) | ||
| Less cost of treatment | 18 (5.1%) | ||
| Not mentioned | 36 (10.2%) | ||
The results of assessment based on CONSORT FOR TCM.
| Paper section and topic | Item | Description | Number (%) |
|---|---|---|---|
| Title and abstract | 1 | Is there abstract or not? | 269 (76.0%) |
| Introduction | |||
| Background | 2 | A brief statement of reasons for trials and medicines | 261 (73.7%) |
| Objectives | 3 | Specific objectives or hypotheses | 237 (66.9%) |
| Methods | |||
| Participants | 4 | Diagnostic criteria of Western medicine | 299 (84.5%) |
| Using the diagnostic criteria and Syndromes of TCM | 151 (42.7%) | ||
| Inclusion criteria | 268 (75.7%) | ||
| Exclusion criteria | 254 (71.8%) | ||
| The settings and location where the data collected | 301 (85.0%) | ||
| Interventions | 5 | Details on interventions of each group (such as dosage, metropolis, concocting method, and batch number) | 161 (45.5%) |
| Strategy of quality control | 5 (1.4%) | ||
| Outcomes | 6 | Clearly defined outcome measures and when applicable | 256 (72.3%) |
| Using the syndrome indicators to evaluate the outcome | 88 (24.9%) | ||
| Sample size | 7 | How sample size was determined | 4 (1.1%) |
| Randomization | |||
| (i) Sequence generation | 8 | Method used to generate the random allocation sequence | 260 (73.4%) |
| (ii) Allocation concealment | 9 | Method used to implement the random allocation sequence | 29 (8.2%) |
| (iii) Implementation | 10 | Who generated the allocation sequence, who enrolled participants, and who assigned participants to their groups? | 12 (3.4%) |
| (iv) Blinding | 11 | Single blinding | 8 (2.3%) |
| Double blinding | 13 (3.7%) | ||
| Not mentioned | 333 (94.1%) | ||
| Statistical methods | 12 | Description of statistical methods | 347 (98.0%) |
| Results | |||
| Participant flow | 13 | Flow of participants' changes in each stage | 90 (25.4%) |
| A diagram of flow | 0 (0.0%) | ||
| Compliance | 15 (4.2%) | ||
| Recruitment | 14 | The method for collection | 6 (1.7%) |
| Follow-up record | 103 (29.1%) | ||
| Baseline data | 15 | Baseline demographic and clinical characteristics of each group | 68 (19.2%) |
| Numbers analyzed | 16 | Whether the analysis was by ‘‘intention-to-treat” | 7 (2.0%) |
| Outcomes and estimation | 17 | Positive results | 352 (99.4%) |
| Negative results | 0 (0.0%) | ||
| Equivalent results | 2 (0.6%) | ||
| The precise of data | 323 (91.2%) | ||
| Give the confidence interval and value of “ | 40 (11.3%) | ||
| Ancillary analyses | 18 | Results of any other analyses performed, including Subgroup analyses and adjusted analyses, distinguishing prespecified from exploratory | 5 (1.4%) |
| Harms | 19 | All important harms or unintended effects in each group | 198 (55.9%) |
| Discussion | |||
| Interpretation | 20 | Interpretation of the results | 353 (99.7%) |
| Explaining the significance in statistics and treatment | 255 (72.0%) | ||
| Explain the results with theories of TCM | 218 (61.6%) | ||
| Potential bias | 28 (7.9%) | ||
| Generalizability | 21 | Generalizability (external validity) of the results | 86 (24.3%) |
| Overall evidence | 22 | Description of the interest conflict between researchers and participants | 0 (0.0%) |
Note: items in Tables 3 and 4 are calculated one by one; few items may cross with each other, so we counted them more than one.